openPR Logo
Press release

Chemotherapy-induced Nausea and Vomiting Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight

06-11-2025 03:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Chemotherapy-induced Nausea and Vomiting Market

Chemotherapy-induced Nausea and Vomiting Market

DelveInsight's "Chemotherapy-Induced Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Chemotherapy-Induced Nausea and Vomiting, historical and forecasted epidemiology as well as the Chemotherapy-Induced Nausea and Vomiting market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock key insights into the Chemotherapy-Induced Nausea and Vomiting Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chemotherapy-Induced Nausea and Vomiting Market Size- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chemotherapy-Induced Nausea and Vomiting Market Report
• In April 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie conducted a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.
• In March 2025, Xiamen LP Pharmaceutical Co., Ltd announced a phase 2 study to compare efficacy, safety and PK of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film compared to iv injection for moderately emetogenic chemotherapy-induced nausea or vomiting (CINV) in cancer patients. Subjects are randomized into three treatment groups, two with the experimental study drug palonosetron in buccal film at one of two different doses or the control treatment using Palonosetron hydrochloride iv injection. Palonosetron PK will be assessed in a subgroup of each treatment group.
• The increase in Chemotherapy-Induced Nausea and Vomiting Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Chemotherapy-Induced Nausea and Vomiting Market is anticipated to witness growth at a considerable CAGR.
• The leading Chemotherapy-Induced Nausea and Vomiting Companies such as GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others.
• Promising Chemotherapy-Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Casopitant, Fosaprepitant Dimeglumine, Intranasal granisetron and others.

Stay ahead in the competitive landscape of the Chemotherapy-Induced Nausea and Vomiting Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chemotherapy-Induced Nausea and Vomiting Treatment Market Size- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-Induced Nausea and Vomiting Epidemiology Segmentation in the 7MM
The epidemiology section of Chemotherapy-Induced Nausea and Vomiting offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Chemotherapy-Induced Nausea and Vomiting epidemiology trends @ Chemotherapy-Induced Nausea and Vomiting Prevalence- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-Induced Nausea and Vomiting Drugs Market
The Chemotherapy-Induced Nausea and Vomiting Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Chemotherapy-Induced Nausea and Vomiting signaling in Chemotherapy-Induced Nausea and Vomiting are likely to uncover new therapeutic targets and further expand treatment options for patients.

Chemotherapy-Induced Nausea and Vomiting Treatment Market Landscape
The Chemotherapy-Induced Nausea and Vomiting treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Chemotherapy-Induced Nausea and Vomiting has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Chemotherapy-Induced Nausea and Vomiting treatment guidelines, visit @ Chemotherapy-Induced Nausea and Vomiting Treatment Market Landscape- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chemotherapy-Induced Nausea and Vomiting Companies
GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others.

Chemotherapy-Induced Nausea and Vomiting Market Outlook
The report's outlook on the Chemotherapy-Induced Nausea and Vomiting market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Chemotherapy-Induced Nausea and Vomiting therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Chemotherapy-Induced Nausea and Vomiting drug and late-stage pipeline therapy.

Chemotherapy-Induced Nausea and Vomiting Drug Uptake
The drug chapter of the Chemotherapy-Induced Nausea and Vomiting report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages and disadvantages of each drug, as well as the latest news and press releases related to Chemotherapy-Induced Nausea and Vomiting.

Explore the dynamics of the Chemotherapy-Induced Nausea and Vomiting Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chemotherapy-Induced Nausea and Vomiting Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/chemotherapy-induced-nausea-and-vomiting-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chemotherapy-Induced Nausea and Vomiting Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Chemotherapy-Induced Nausea and Vomiting Companies- GlaxoSmithKline, Xiamen LP Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Shin Nippon Biomedical Laboratories Ltd., Solvay Pharmaceuticals, Solasia Pharma K.K., Helsinn Healthcare SA, Tesaro Inc., Heron Therapeutics and others
• Chemotherapy-Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Casopitant, Fosaprepitant Dimeglumine, Intranasal granisetron and others.
• Chemotherapy-Induced Nausea and Vomiting Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Chemotherapy-Induced Nausea and Vomiting Unmet Needs, KOL's views, Analyst's views, Chemotherapy-Induced Nausea and Vomiting Market Access and Reimbursement

Table of Content
1. Key Insights
2. Executive Summary of Chemotherapy-Induced Nausea and Vomiting
3. Competitive Intelligence Analysis for Chemotherapy-Induced Nausea and Vomiting
4. Chemotherapy-Induced Nausea and Vomiting: Market Overview at a Glance
5. Chemotherapy-Induced Nausea and Vomiting: Disease Background and Overview
6. Chemotherapy-Induced Nausea and Vomiting Patient Journey
7. Chemotherapy-Induced Nausea and Vomiting Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy-Induced Nausea and Vomiting Unmet Needs
10. Key Endpoints of Chemotherapy-Induced Nausea and Vomiting Treatment
11. Chemotherapy-Induced Nausea and Vomiting Marketed Products
12. Chemotherapy-Induced Nausea and Vomiting Emerging Therapies
13. Chemotherapy-Induced Nausea and Vomiting: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Chemotherapy-Induced Nausea and Vomiting Market Outlook
16. Access and Reimbursement Overview of Chemotherapy-Induced Nausea and Vomiting
17. Chemotherapy-Induced Nausea and Vomiting KOL Views
18. Chemotherapy-Induced Nausea and Vomiting Market Drivers
19. Chemotherapy-Induced Nausea and Vomiting Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Myelodysplastic Syndrome With Excess Blasts2 Market- https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
Neurofibrosarcoma Market- https://www.delveinsight.com/report-store/neurofibrosarcoma-market
Rabies Virus Market- https://www.delveinsight.com/report-store/rabies-infection-market
Liver Angiosarcoma Market- https://www.delveinsight.com/report-store/liver-cancer-market
Eisenmenger Complex Market- https://www.delveinsight.com/sample-request/eisenmenger-complex-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pelvic Inflammatory Disease Market- https://www.delveinsight.com/report-store/chlamydia-market
Neurovascular Catheters Market- https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
Uterine Fibroids Treatment Devices Market- https://www.delveinsight.com/report-store/endometrial-ablation-devices-market
Tadekinig Alfa Market- https://www.delveinsight.com/sample-request/tadekinig-alfa-emerging-insight-and-market-forecast
Dermatomycoses Market- https://www.delveinsight.com/report-store/dermatomyositis-market
Menopause Market- https://www.delveinsight.com/report-store/menopause-market-forecast
Muscle Atrophy/ Wasting Syndrome Market- https://www.delveinsight.com/report-store/sarcopenia-market
Pleural Diseases Market - https://www.delveinsight.com/report-store/malignant-pleural-effusion-market
Orthopedic Splints Device Market- https://www.delveinsight.com/report-store/orthotic-devices-market
Inflammatory Bowel Disease Market- https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market
Liquid Biospy For Cancer Diagnostics Market- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
Vascular Graft Devices Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Blood Glucose Monitoring Systems Market- https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
Breast Pumps Market- https://www.delveinsight.com/report-store/breast-pumps-market
Obesity Market- https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Adalimumab Biosimilar- https://www.delveinsight.com/report-store/adalimumab-biosimilars-insight
ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Adamantinoma Market- https://www.delveinsight.com/sample-request/adamantinoma-market
Cataract Market- https://www.delveinsight.com/report-store/cataract-surgery-devices-market
Mitochondrial Myopathies Market- https://www.delveinsight.com/report-store/mitochondrial-myopathies-market
Optic Atropy Market- https://www.delveinsight.com/report-store/autosomal-dominant-optic-atrophy-market
Transfusion-dependent Thalassaemia Market- https://www.delveinsight.com/report-store/transfusion-dependent-thalassaemia-market
Acute Pain Market- https://www.delveinsight.com/report-store/acute-pain-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chemotherapy-induced Nausea and Vomiting Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight here

News-ID: 4061928 • Views:

More Releases from DelveInsight Business Research LLP

Germ Cell Tumors Market: Epidemiology, Therapies, Companies, DelveInsight | Takeda Pharmaceutical Company Limited, Novartis, Bristol Myers Squibb, Merck & Co., Inc., Roche, Bayer
Germ Cell Tumors Market: Epidemiology, Therapies, Companies, DelveInsight | Take …
Germ Cell Tumors emerging therapies such as Cabozantinib, are expected to boost the Germ Cell Tumors Market in the upcoming years. DelveInsight has launched a new report on "Germ Cell Tumors - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Germ Cell Tumors, historical and forecasted epidemiology as well as the Germ Cell Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and
Giant Cell Arteritis Pipeline 2025: Groundbreaking Clinical Advancements by 80+ Global Leaders - DelveInsight | Featuring Novartis, AbbVie, XOMA, Kiniksa Pharmaceuticals, Ltd., Eli Lilly and Company, Janssen Biotech, Dr Reddys Laboratories
Giant Cell Arteritis Pipeline 2025: Groundbreaking Clinical Advancements by 80+ …
With Giant Cell Arteritis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Giant Cell Arteritis pipeline comprises 6+ pharmaceutical and biotech companies actively developing 6+ therapeutic candidates targeting Giant Cell Arteritis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation
Pheochromocytoma Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Global Leaders - DelveInsight | Featuring Enterome, Perspective Therapeutics
Pheochromocytoma Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Globa …
With Pheochromocytoma reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Pheochromocytoma pipeline comprises 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting Pheochromocytoma. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of
Presbyopia Pipeline 2025: Groundbreaking Clinical Advancements by 10+ Global Leaders - DelveInsight | Featuring Visus Therapeutics, Glaukos Corporation, Cellix Bio, Orasis Pharmaceuticals, Cellix Bio
Presbyopia Pipeline 2025: Groundbreaking Clinical Advancements by 10+ Global Lea …
With Presbyopia reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Presbyopia pipeline comprises 10+ pharmaceutical and biotech companies actively developing 10+ therapeutic candidates targeting Presbyopia. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of

All 5 Releases


More Releases for Nausea

Nausea And Vomiting Treatment Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Nausea And Vomiting Treatment Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Nausea And Vomiting Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Nausea And Vomiting
Chemotherapy-Induced Nausea And Vomiting Therapeutics Market– Innovation Surve …
Cancer is a leading cause of death worldwide, accounting nearly 1.4 million new cases in 2012. The most common cause of cancer is lung cancer accounting about 1.59 million deaths, globally. Other prominent cancers are liver cancer, breast cancer, stomach cancer, esophageal and stomach cancer. In 2012, nearly 8.2 million deaths occurred from aforementioned indication, globally. Cancer can be treated by surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, precision
Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea an …
The report “Global Chemotherapy-Induced Nausea and Vomiting (CINV) & Postoperative Nausea and Vomiting (PONV) Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. Inquire for a discount on this CINV & PONV Market report at http://www.marketreportsonline.com/contacts/discount.php?name=745672. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with
Nausea Medicine Market Comprehensive Analysis & Global Forecast to 2023
Market Research Future has a half cooked research report on the global nausea medicine market. The global nausea medicine market is growing continuously and expected to grow at a CAGR of 7.2% from 2017 to 2023. Market Synopsis of the Global Nausea Medicine Market The Global Nausea Medicine Market is expected to grow at a CAGR of 7.2% during the forecast period. Nausea is a state of stomach distress with an urge to
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape. Chemotherapy induced nausea and vomiting or CINV is nausea and
Chemotherapy-induced Nausea and Vomiting Drugs Market 2017
Market Research Analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021. According to the report, the high unmet medical need in the market has driven the R&D activities of existing as well as new vendors. Helsinn is one of the leading companies that has a strong pipeline of CINV drugs with two drug candidates in Phase III and Phase I stages. Helsinn